Cystic Fibrosis Pulmonary Exacerbation Clinical Trials
2 recruiting trials for Cystic Fibrosis Pulmonary Exacerbation. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Cystic Fibrosis Pulmonary Exacerbation clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 4 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Chris Goss (1), University of Colorado, Denver (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Beta-lactam antibiotic (drug, 1 trial), followed by Aminoglycoside.
Track Cystic Fibrosis Pulmonary Exacerbation trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a...
Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations
The goal of this study is to investigate the prevalence of dysglycemia with continuous glucose monitoring (CGM) obtained during pulmonary exacerbations, both outpatient and...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Cystic Fibrosis Pulmonary Exacerbation, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Cystic Fibrosis Pulmonary Exacerbation, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Cystic Fibrosis Pulmonary Exacerbation, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.